Deborah Doroshow, MD, PhD is an Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai, New York, NY and Adjunct Assistant Professor of the History of Medicine at the Yale University School of Medicine, New Haven, CT.
Dr Doroshow completed her PhD in the History of Science and Medicine from Yale University. Subsequently, she obtained her MD from Harvard Medical School, Boston, MA, before completing an internship and a residency in internal medicine at the Yale University School of Medicine. Following this, she completed a fellowship in hematology and oncology, also at the Yale University School of Medicine.
Speaking on novel chemotherapeutic agents for the treatment of genitourinary cancers
Dr Doroshow’s interests lie in the treatment of adults with lung cancer as well as adults with a variety of solid tumors as part of the Early Phase Trials Unit, where her work focuses on the DNA damage response. Recently, Dr Doroshow’s research has focused on PD-L1 expression in tumor or immune cells, and its role as a biomarker of response to immune-checkpoint inhibitors, as well as novel agents targeting DNA damage and repair processes.